Essilor - News Release: Capital Increase Reserved for Employees
12 Dicembre 2017 - 06:00PM
Capital Increase
Reserved for Employees
PDF Version of the news release
Charenton-le-Pont, France (December 12, 2017 - 6:00
p.m.) - At the Extraordinary General Meeting of May 11,
2017, shareholders of Essilor International (Compagnie Générale
d'Optique) ("Essilor") authorized the Board of Directors, within a
26-month period, to issue shares reserved for employees
participating in an Essilor employee stock ownership plan, with new
shares representing up to 1.5% of the total capital stock
(Resolution 18)[1]. The
maximum number of common shares previously authorized for issuance
was 3,107,595[2].
At its meeting of December 6, 2017, the Board of Directors decided
to issue up to 350,000 common shares reserved for participants in
the Essilor / Essilor International[3] / BBGR /
Novacel Ophtalmique / BNL Eurolens / Delamare Sovra SAS / Mont
Royal / EOMC / DAC Vision / Transitions Optical Distribution Ltd
employee stock ownership plans. The new shares will carry dividend
rights from January 1, 2017. They will be offered at a price of
€85.71 per share, this being the average of the opening prices over
the 20 trading days preceding the Board's December 6, 2017 meeting,
to which a 20% discount has been applied.
The purpose of this offer is to
further involve the Company's employees in its development by
allowing them to become shareholders. The shares can be purchased
through two funds. These funds have been given a specific value
since January 1, 2017, the start date of the subscription period.
The closing date of the subscription period was December 11, 2017.
The actual number of shares issued will be announced on December
22, 2017, after which the Company will apply for the new shares
(par value: €0.18) to be listed on Euronext Paris.
The Company's capital stock
amounts to €39,374,683.38, represented by 218,748,241 shares as of
November 30, 2017².
About Essilor
Essilor International (Compagnie Générale
d'Optique) ("Essilor") is the world's leading ophthalmic optics
company. Essilor designs, manufactures and markets a wide range of
lenses to improve and protect eyesight. Its mission is to improve
lives by improving sight. To support this mission, Essilor
allocates more than €200 million to research and innovation every
year, in a commitment to continuously bring new, more effective
products to market. Its flagship brands are Varilux®,
Crizal®,
Transitions®,
EyezenTM,
Xperio®, Foster
Grant®,
BolonTM and
Costa®. It also
develops and markets equipment, instruments and services for
eyecare professionals.
Essilor reported consolidated revenue of more than
€7.1 billion in 2016 and employs approximately 64,000 people
worldwide. It markets its products in more than 100 countries and
has 33 plants, 490 prescription laboratories and edging facilities,
as well as 5 research and development centers around the world (as
of December 31, 2016). For more information, please visit
www.essilor.com.
The Essilor International share trades on the
Euronext Paris market and is included in the Euro Stoxx 50 and CAC
40 indices.
Codes and symbols: ISIN: FR0000121667; Reuters:
ESSI.PA; Bloomberg: EI:FP.
------------------------
Investor Relations and Financial
Communications
Phone: +33 (0)1 49 77 42 16
[1] Common ceiling applying to resolutions 18 and 19 adopted by
the Extraordinary General Meeting of May 11, 2017
[2] Following the capital increase on November 30, 2017, as
authorized by resolution 19 adopted by the Extraordinary General
Meeting of May 11, 2017 (see press release issued on November
21, 2017)
[3] A French simplified joint-stock company (société par
actions simplifiée) registered with the Créteil Trade and Companies
Register (Registre du Commerce et des Sociétés) under number 439
769 654
PDF Version of the news
release
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Essilor International via Globenewswire